288 related articles for article (PubMed ID: 36097853)
1. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
[TBL] [Abstract][Full Text] [Related]
2. Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance.
Mendes D; Chapman R; Aruffo E; Gal P; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
Expert Rev Vaccines; 2023; 22(1):90-103. PubMed ID: 36519401
[TBL] [Abstract][Full Text] [Related]
3. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
[TBL] [Abstract][Full Text] [Related]
4. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
[TBL] [Abstract][Full Text] [Related]
5. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
7. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
8. Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns.
Mendes D; Machira Krishnan S; O'Brien E; Padgett T; Harrison C; Strain WD; Manca A; Ustianowski A; Butfield R; Hamson E; Reynard C; Yang J
Infect Dis Ther; 2024 May; 13(5):1127-1146. PubMed ID: 38662331
[TBL] [Abstract][Full Text] [Related]
9. Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination.
Fitzpatrick MC; Moghadas SM; Vilches TN; Shah A; Pandey A; Galvani AP
JAMA Netw Open; 2023 May; 6(5):e2313586. PubMed ID: 37204795
[TBL] [Abstract][Full Text] [Related]
10. Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.
Steele MK; Couture A; Reed C; Iuliano D; Whitaker M; Fast H; Hall AJ; MacNeil A; Cadwell B; Marks KJ; Silk BJ
JAMA Netw Open; 2022 Jul; 5(7):e2220385. PubMed ID: 35793085
[TBL] [Abstract][Full Text] [Related]
11. Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore.
Thakkar K; Spinardi J; Kyaw MH; Yang J; Mendoza CF; Ozbilgili E; Taysi B; Dodd J; Yarnoff B; Oh HM
Expert Rev Vaccines; 2024; 23(1):16-26. PubMed ID: 38047434
[TBL] [Abstract][Full Text] [Related]
12. Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.
Milne GJ; Carrivick J; Whyatt D
BMC Med; 2022 Feb; 20(1):80. PubMed ID: 35177062
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
15. Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths.
Brault A; Hart A; Uribe P; Prado J; San Martín J; Maass A; Canals M
BMC Infect Dis; 2024 May; 24(1):467. PubMed ID: 38698324
[TBL] [Abstract][Full Text] [Related]
16. Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand.
Thakkar K; Spinardi J; Kyaw MH; Yang J; Mendoza CF; Ozbilgili E; Dodd J; Yarnoff B; Punrin S
Expert Rev Vaccines; 2023; 22(1):860-870. PubMed ID: 37779484
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021.
Johnson AG; Amin AB; Ali AR; Hoots B; Cadwell BL; Arora S; Avoundjian T; Awofeso AO; Barnes J; Bayoumi NS; Busen K; Chang C; Cima M; Crockett M; Cronquist A; Davidson S; Davis E; Delgadillo J; Dorabawila V; Drenzek C; Eisenstein L; Fast HE; Gent A; Hand J; Hoefer D; Holtzman C; Jara A; Jones A; Kamal-Ahmed I; Kangas S; Kanishka F; Kaur R; Khan S; King J; Kirkendall S; Klioueva A; Kocharian A; Kwon FY; Logan J; Lyons BC; Lyons S; May A; McCormick D; ; Mendoza E; Milroy L; O'Donnell A; Pike M; Pogosjans S; Saupe A; Sell J; Smith E; Sosin DM; Stanislawski E; Steele MK; Stephenson M; Stout A; Strand K; Tilakaratne BP; Turner K; Vest H; Warner S; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):132-138. PubMed ID: 35085223
[TBL] [Abstract][Full Text] [Related]
18. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
[TBL] [Abstract][Full Text] [Related]
19. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
20. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
